TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3317958

Group type: EXPERIMENTAL
Intervention: Lugol's iodine, 0.3 ml thrice daily for 9 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31654634

Group type: EXPERIMENTAL
Intervention: 22-gauge Franseen needle
Number of subjects: 110

Group type: COMPARATOR
Intervention: 20-gauge forward-bevel needle
Number of subjects: 110
Study: 29542111

Group type: EXPERIMENTAL
Intervention: Home-based community paramedicine program (EPIC)
Number of subjects: 30
Study: 28622956

Group type: EXPERIMENTAL
Intervention: 9-month physical activity intervention
Number of subjects: 154

Group type: COMPARATOR
Intervention: Waitlist-control condition
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: 9-month physical activity intervention (obese participants)
Number of subjects: 154
Study: 26652073

Group type: EXPERIMENTAL
Intervention: Health Promotion Program (HPP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 24016490

Group type: EXPERIMENTAL
Intervention: Aleglitazar 150 μg daily in addition to standard medical therapy
Number of subjects: 7228

Group type: COMPARATOR
Intervention: Placebo daily in addition to standard medical therapy
Number of subjects: 7228

Group type: EXPERIMENTAL
Intervention: Aleglitazar 150 μg daily
Number of subjects: 7228

Group type: COMPARATOR
Intervention: Placebo daily
Number of subjects: 7228
Study: 21980798

Group type: EXPERIMENTAL
Intervention: Specific sublingual immunotherapy (SLITOne, ALK) for two consecutive pollen seasons
Number of subjects: 162
Study: 18506425

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 20
Study: 15626611

Group type: EXPERIMENTAL
Intervention: Bioelectronic sniffers incorporating alcohol oxidase (AOD) for measuring ethanol vapor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bioelectronic sniffers incorporating aldehyde dehydrogenase (ALDH) for measuring acetaldehyde
Number of subjects: 0
Study: 12147928

Group type: EXPERIMENTAL
Intervention: Patient self-reported blood pressures
Number of subjects: 49
Study: 10356376

Group type: EXPERIMENTAL
Intervention: Classical acupuncture
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 29
Study: 7626592

Group type: COMPARATOR
Intervention: Psyllium and psyllium-citrus pectin mixture (2.2 g)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sugar-beet fibre (6 g)
Number of subjects: 28
Study: 1782972

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 75 micrograms/h (Fentanyl‐TTS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7075190

Group type: EXPERIMENTAL
Intervention: 0.5 mg Sulprostone at 4 hourly intervals for 8 doses
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 1.0 mg Sulprostone at 8-hour intervals for 4 doses
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Sulprostone (both doses)
Number of subjects: 56
Study: 31058986

Group type: EXPERIMENTAL
Intervention: Spray 1
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Spray 2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lotion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cream
Number of subjects: 24
Study: 31694576

Group type: EXPERIMENTAL
Intervention: INH/100 (8% sevoflurane in 100% oxygen)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: INH/50 (8% sevoflurane in 50% oxygen and 50% nitrous oxide)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Phnl/PROP (2.2 mg/kg propofol preceded by 160 mcg phenylephrine)
Number of subjects: 200

Group type: COMPARATOR
Intervention: PROP (2.2 mg/kg propofol)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: INH/100, INH/50, Phnl/PROP (combined)
Number of subjects: 200
Study: 28391968

Group type: EXPERIMENTAL
Intervention: Physical victimization
Number of subjects: 11110

Group type: EXPERIMENTAL
Intervention: Relational victimization
Number of subjects: 11110

Group type: EXPERIMENTAL
Intervention: Verbal victimization
Number of subjects: 11110

Group type: EXPERIMENTAL
Intervention: Low peer support
Number of subjects: 11110
Study: 25968340

Group type: EXPERIMENTAL
Intervention: Oral propranolol
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (no oral propranolol)
Number of subjects: 71
Study: 23482590

Group type: EXPERIMENTAL
Intervention: AG (1, 3, and 5 μg/kg per h) infused over 65 min
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: AG (1 μg/kg per h) infused over 210 min
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: DAG (4 μg/kg per h) infused over 210 min
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both AG and DAG infused over 210 min
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ghrelin administration
Number of subjects: 22
Study: 21715189

Group type: EXPERIMENTAL
Intervention: Primary repair (PR)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: SIS buttressed repair
Number of subjects: 72
Study: 19194213

Group type: EXPERIMENTAL
Intervention: 131I
Number of subjects: 460

Group type: COMPARATOR
Intervention: ATD
Number of subjects: 460
Study: 17011324

Group type: EXPERIMENTAL
Intervention: Swaddling
Number of subjects: 398

Group type: COMPARATOR
Intervention: Standardized approach without swaddling
Number of subjects: 398
Study: 15335127

Group type: EXPERIMENTAL
Intervention: Chronic care model for depression implemented in practices
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Chronic care model for depression
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Change strategy supporting practice change
Number of subjects: 180
Study: 11352778

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (125 ml, tds) co-administered with indomethacin (50 mg, tds)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Indomethacin (50 mg, tds) with whey protein (control)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Colostral solutions (125 ml, tds)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control solutions (125 ml, tds)
Number of subjects: 22
Study: 9209895

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide (MTC) intravenous bolus after a 2-h saline infusion
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 4-h dopamine infusion at 0.01 microgram/kg/min with a 10 mg intravenous bolus of MTC given at the second hour of dopamine infusion
Number of subjects: 39

Group type: COMPARATOR
Intervention: 4-h saline infusion
Number of subjects: 39
Study: 8352298

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 42

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 42
Study: 3610737

Group type: EXPERIMENTAL
Intervention: 35 micrograms ethinyl estradiol and 0.5 mg norethindrone
Number of subjects: 55

Group type: COMPARATOR
Intervention: 50 micrograms mestranol and 1.0 mg norethindrone
Number of subjects: 55
Study: 28296201

Group type: EXPERIMENTAL
Intervention: Combination therapy with lixisenatide and basal insulin (LIX group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Multiple daily insulin injection therapy (MDI group)
Number of subjects: 31
Study: 27496696

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (Movement Coaching)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Low intensity intervention
Number of subjects: 412
Study: 24468198

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Program (CDSMP)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Personal Digital Assistant (PDA)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Combined PDA and CDSMP (COM)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 376
Study: 23714399

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) + Reduced tacrolimus (TAC)
Number of subjects: 245

Group type: COMPARATOR
Intervention: TAC Control
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) + Reduced TAC
Number of subjects: 245
Study: 21071167

Group type: EXPERIMENTAL
Intervention: Narrative video (Living Proof)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Informational video (Facts for Life)
Number of subjects: 489
Study: 18411832

Group type: EXPERIMENTAL
Intervention: Immediate intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 24
Study: 16607077

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 0
Study: 15052977

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 70

Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pharmacological treatment
Number of subjects: 70
Study: 11025358

Group type: EXPERIMENTAL
Intervention: Modified Sham Feeding (MSF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycemia
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control experiment
Number of subjects: 8
Study: 8851899

Group type: EXPERIMENTAL
Intervention: 25% of isometric maximal voluntary contraction (MVC) at 40 degrees/second
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 50% of isometric maximal voluntary contraction (MVC) at 40 degrees/second
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 25% of isometric maximal voluntary contraction (MVC) at 80 degrees/second
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 50% of isometric maximal voluntary contraction (MVC) at 80 degrees/second
Number of subjects: 7

Group type: COMPARATOR
Intervention: Contraction velocity (40 vs 80 degrees/second)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Force decrement during the test-contraction
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: EMG amplitude during counter movement at high forces and high velocities
Number of subjects: 7

Group type: COMPARATOR
Intervention: Frequency content of EMG signals during dynamic contractions and postexercise test-contraction
Number of subjects: 7
Study: 1933162

Group type: EXPERIMENTAL
Intervention: Antazoline sclerotherapy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 92

Group type: COMPARATOR
Intervention: Aspiration
Number of subjects: 92
Study: 93043

Group type: EXPERIMENTAL
Intervention: tocainide (400 or 600 mg every eight hours)
Number of subjects: 12
Study: 31950776

Group type: EXPERIMENTAL
Intervention: Direct management by intensivists without residents
Number of subjects: 314

Group type: COMPARATOR
Intervention: Resident management under high-intensity intensivist staffing
Number of subjects: 314
Study: 29695175

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (treatment-as-usual)
Number of subjects: 66
Study: 28487139

Group type: EXPERIMENTAL
Intervention: Ramped position (head of the bed elevated to 25°)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Sniffing position (torso supine, neck flexed, and head extended)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Ramped position
Number of subjects: 260

Group type: COMPARATOR
Intervention: Sniffing position
Number of subjects: 260
Study: 26076171

Group type: EXPERIMENTAL
Intervention: Tapentadol (100 mg immediate release tablet)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Morphine (40 mg immediate release tablet)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23507370

Group type: EXPERIMENTAL
Intervention: Active tDCS treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study: 21444883

Group type: EXPERIMENTAL
Intervention: Remote telemedical management (RTM)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 710
Study: 19429451

Group type: EXPERIMENTAL
Intervention: High-volume upper-body resistance exercise (HT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (CON) trial
Number of subjects: 6
Study: 16420392

Group type: EXPERIMENTAL
Intervention: Cerebrolysin 10 ml
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Cerebrolysin 30 ml
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Cerebrolysin 60 ml
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 16162200

Group type: EXPERIMENTAL
Intervention: Sirolimus-based immunosuppression
Number of subjects: 40

Group type: COMPARATOR
Intervention: CNI-based immunosuppression (cyclosporin or tacrolimus)
Number of subjects: 40
Study: 12777437

Group type: EXPERIMENTAL
Intervention: Follow-up survey in 1997
Number of subjects: 3499

Group type: EXPERIMENTAL
Intervention: Baseline risk factors
Number of subjects: 3499
Study: 9674619

Group type: EXPERIMENTAL
Intervention: Mailed intervention containing guidelines for the use of sedative hypnotics, a prescriber profile detailing sedative hypnotic prescribing, and a patient profile
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Mailed intervention
Number of subjects: 189
Study: 7639342

Group type: EXPERIMENTAL
Intervention: 600 mg d-alpha-tocopherol per day for 3 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 800 mg d-alpha-tocopherol per day for 3 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1200 mg d-alpha-tocopherol per day for 3 weeks
Number of subjects: 15
Study: 2515041

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 250 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cefotaxime 500 mg
Number of subjects: 65
Study: 340329

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg daily at bedtime
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30093372

Group type: EXPERIMENTAL
Intervention: iPST (problem-solving therapy)
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Project Evolution (cognitive training app)
Number of subjects: 1040

Group type: COMPARATOR
Intervention: Health tips (information control)
Number of subjects: 1040
Study: 29691559

Group type: EXPERIMENTAL
Intervention: Nd:YAP laser disinfection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hoshino's triple antibiotic paste (Control)
Number of subjects: 40
Study: 26261326

Group type: EXPERIMENTAL
Intervention: Evocative messages delivered on stickers inside matatus
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Complementary radio campaign
Number of subjects: 12000
Study: 23770747

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 5851

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice daily
Number of subjects: 5851
Study: 21111873

Group type: EXPERIMENTAL
Intervention: Placement of informational posters in endoscopy rooms within view of operators and nurses.
Number of subjects: 778

Group type: COMPARATOR
Intervention: Control group (historical cohort).
Number of subjects: 778
Study: 18807742

Group type: EXPERIMENTAL
Intervention: Cough of > or = 14 days in survey I
Number of subjects: 82000

Group type: EXPERIMENTAL
Intervention: Symptomatic subjects with cough in surveys II and III
Number of subjects: 82000

Group type: EXPERIMENTAL
Intervention: Symptoms without cough but with chest pain > or = 1 month in survey I
Number of subjects: 82000

Group type: EXPERIMENTAL
Intervention: Symptoms without cough but with chest pain > or = 1 month in survey II
Number of subjects: 82000

Group type: EXPERIMENTAL
Intervention: Symptoms without cough but with chest pain > or = 1 month in survey III
Number of subjects: 82000

Group type: EXPERIMENTAL
Intervention: Fever > or = 1 month
Number of subjects: 82000
Study: 16162703

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 mug)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 14587651

Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nifedipine SR (20 mg/day)
Number of subjects: 60
Study: 10566466

Group type: EXPERIMENTAL
Intervention: Access to pain management information on the ambulatory surgery website
Number of subjects: 195
Study: 8722940

Group type: EXPERIMENTAL
Intervention: HRC regimen (isoniazid 300 mg, rifampin 600 mg, ciprofloxacin 750 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: HRZE regimen (isoniazid 300 mg, rifampin 600 mg, pyrazinamide 25 mg/kg, ethambutol 15 mg/kg)
Number of subjects: 200
Study: 1910795

Group type: EXPERIMENTAL
Intervention: 360 ml of apple juice, 150 mg of oral ranitidine (two doses), 10 mg of metoclopramide
Number of subjects: 83

Group type: COMPARATOR
Intervention: Fasting with acid aspiration prophylaxis identical to Group 1
Number of subjects: 83

Group type: COMPARATOR
Intervention: No oral fluids or acid aspiration prophylaxis
Number of subjects: 83
Study: 6761928

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 2 mg pessaries administered four hourly
Number of subjects: 0
Study: 30489177

Group type: EXPERIMENTAL
Intervention: Tofacitinib low-dose (1 or 3 mg) with low-dose MTX
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Tofacitinib low-dose (1 or 3 mg) with high-dose MTX
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID with low-dose MTX
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID with high-dose MTX
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID with low-dose MTX
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID with high-dose MTX
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo with low-dose MTX
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo with high-dose MTX
Number of subjects: 254
Study: 27913227

Group type: EXPERIMENTAL
Intervention: Immediate assisted partner services
Number of subjects: 1305

Group type: COMPARATOR
Intervention: Delayed assisted partner services
Number of subjects: 1305
Study: 25813240

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (L.GG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23939544

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 17
Study: 22979911

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (15% cetrimide, 1.5% Chlorhexidine-gluconate, ethanol)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Povidone-iodine (10% povidone-iodine)
Number of subjects: 50
Study: 19407731

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole (2-20 mg/day)
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 1147
Study: 17387446

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study: 16279260

Group type: EXPERIMENTAL
Intervention: Eformoterol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 10769852

Group type: EXPERIMENTAL
Intervention: Toothbrushing
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Professional cleaning with a rubber cup
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Scaling
Number of subjects: 155
Study: 9060541

Group type: EXPERIMENTAL
Intervention: Adjuvant goserelin
Number of subjects: 945

Group type: COMPARATOR
Intervention: Observation arm
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Adjuvant goserelin (in patients with Gleason score 8 to 10)
Number of subjects: 945

Group type: COMPARATOR
Intervention: Observation arm (in patients with Gleason score 8 to 10)
Number of subjects: 945
Study: 8394849

Group type: EXPERIMENTAL
Intervention: Dalteparin sodium (10,000 IU daily for weeks 1 and 2, 5,000 IU daily for weeks 3 and 4)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dalteparin sodium
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 3097709

Group type: EXPERIMENTAL
Intervention: Naloxone (0.03 mg/kg body wt.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 6
Study: 28675892

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eurythmy therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiotherapeutic exercises
Number of subjects: 0
Study: 27391158

Group type: EXPERIMENTAL
Intervention: CRT plus consolidation chemotherapy
Number of subjects: 146

Group type: COMPARATOR
Intervention: CRT alone
Number of subjects: 146
Study: 24535848

Group type: EXPERIMENTAL
Intervention: Psychoeducation using a tablet PC during chemotherapy infusion (n=19)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (n=17)
Number of subjects: 36
Study: 22728750

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo (for both albendazole and praziquantel)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Hookworm and Trichuris infections
Number of subjects: 264
Study: 20083245

Group type: EXPERIMENTAL
Intervention: TiF4
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ZrF4
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HfF4
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AmF
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (unfluoridated samples)
Number of subjects: 10
Study: 18932271

Group type: EXPERIMENTAL
Intervention: Rasagiline (neuroprotective therapy)
Number of subjects: 1176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1176
Study: 15800147

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Nonspecific supportive clinical management
Number of subjects: 56
Study: 12870166

Group type: EXPERIMENTAL
Intervention: 20% Intralipid infusion (0.4 mL(‐1) x kg(‐1) x h(‐1))
Number of subjects: 15
Study: 10420420

Group type: EXPERIMENTAL
Intervention: Three-dose emotional expression writing group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Single dose emotional expression writing group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Attentional control group
Number of subjects: 44
Study: 7594351

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 93

Group type: COMPARATOR
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 93
Study: 1966304

Group type: EXPERIMENTAL
Intervention: Premarin
Number of subjects: 11
Study: 7194061

Group type: EXPERIMENTAL
Intervention: etofylline clofibrate (3 x 250 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: standard preparation (clofibrate 3 x 500 mg and beta-pyridylcarbinol hydrogentartrate 3 x 25 mg)
Number of subjects: 20